MedPage Today reports that thiazolidinediones (aka glitazones) are linked to development of bladder cancer. Pioglitazone is the most commonly used TZD in the U.S. From the article:
The increased risk of bladder cancer associated with glitazones — which reached a relative increase of 72% in patients who started on the agents more than 5 years earlier — “appears to be a class effect,” the research team, led by Ronac Mamtani, MD, of the University of Pennsylvania in Philadelphia, concluded.
According to the National Cancer Institute, the U.S. has 74,000 new cases of bladder cancer yearly, and 15,000 annual deaths from bladder cancer.
If you take a thiazolidinedione, talk to your doctor about bladder cancer at your next visit.